Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin in Severe Insulin Resistance
NCT00085982Phase 2Active, not recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Aug 2003
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metreleptin in insulin resistance (IR), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Hemoglobin A1c at 1 year. Started Aug 2003; status: active, not recruiting.
02
Drugs
metreleptin
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT00085982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085982.